ClinicalTrials.gg
CompletedNCT01464983Updated Dec 25, 2014

Placebo and Active Controlled, Double Dummy Study to Compare Efficacy of Aspirin and Ibuprofen in Treatment of Episodic Tension-type Headache

A Phase 4 interventional study of Acetylsalicylic acid (Aspirin, BAYE4465) and Acetylsalicylic acid (Aspirin, BAYE4465) in Headache, Tension-Type Headache and Tension-Type Headache (Episodic), sponsored by Bayer. Completed at 11 sites in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-12-25.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,115
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies in Headache with a site in United Kingdom — none open to participants now, none under way, none of them phase 3. Headache · United Kingdom.

Enrollment
3rd of 24
1,115 · median 345
Started
2004
the only one that year
Phase 4
5 of 25
none open now
Registered
6th of 25
by date
Lead sponsor
2 of 25
Bayer

Among the 25 studies in Headache with a site in United Kingdom, this one is the 3rd largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2004, is one of 5 in phase 4, and was the 6th registered.

Headache

762 studies on the registry are indexed under Headache; 134 are open to participants now.

Browse Headache studies →

Open to participants now

None of the 25 studies in Headache with a site in United Kingdom is open now. The open studies under Headache, anywhere →

Who these studies take

Of the 83 Headache studies recruiting now, 30 (36%) set no upper age limit and 44 (53%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies in Headache with a site in United Kingdom as a file.
02

Study summary

The purpose of this study is to determine the efficacy and tolerability of 500 mg and 1000 mg Aspirin® (study medication) by comparing it to placebo (the control group without active substance) or 200 mg or 400 mg Ibuprofen (study medication) in treating the symptoms of episodic tension-type headache. The study is designed to develop a treatment method against episodic tension-type headache which will have more advantages for patients than the methods that are currently available.

03

Conditions studied

  • Headache
  • Tension-Type Headache
  • Tension-Type Headache (Episodic)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory male or female, 18 to 65 years of age
  • Normal blood pressure
  • Patients suffering from episodic tension-type headache
  • Headache lasting from 30 minutes to 7 days
  • Headache had at least two of the following characteristics:

Bilateral location. Pressing/tightening (non-pulsating). Mild or moderate intensity. Not aggravated by routine physical activity such as walking or climbing stairs.

  • Both of the following: No nausea or vomiting. No more than one of photophobia or phonophobia.

Exclusion criteria

Exclusion Criteria:

  • Other headaches, including migraine, that required medical treatment
  • to acetylsalicylic acid, salicylates, ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs)
  • Serious physical illness especially uncontrolled disorders of kidney, liver, lung, heart or brain function, neurological disorders or severe chronic or terminal disease
  • Mental illness, including depression
  • Needed or were using or likely to need or use any of the prohibited concomitant medications: antidepressants, oxicams
  • Pregnant or lactating women, or sexually active women of unless using effective
  • Participating in any other clinical study or had done within the previous 4 weeks
  • Had been previously enrolled in this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,115 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Drug: Acetylsalicylic acid (Aspirin, BAYE4465)

  • Experimental
    Arm 2

    Drug: Acetylsalicylic acid (Aspirin, BAYE4465)

  • Active comparator
    Arm 3

    Drug: Ibuprofen

  • Active comparator
    Arm 4

    Drug: Ibuprofen

  • Placebo comparator
    Arm 5

    Drug: Placebo

Interventions

  • Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen

  • Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen

  • Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid

  • Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid

  • DrugPlacebo

    2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with total or meaningful headache relief at 2 hours after intake of study medication

    Time frame: 2 hours post dose

Secondary outcomes

  1. Headache pain relief measured serially on a categorical scale

    Time frame: Until 4 hours post dose

  2. Measuring the functional ability on conducting everydays activity on a 4 point categorical scale

    Time frame: 2 and 24 hours post dose

  3. Global assessment of pain therapy

    Time frame: 24 hours post dose

  4. Safety - assessment of adverse events

    Time frame: Up to 10 weeks after screening

07

Study locations

11 sites
  • Reading, Berkshire RG2 7AG, United Kingdom
  • Manchester, Greater Manchester M15 6SX, United Kingdom
  • Chorley, Lancashire PR7 1NY, United Kingdom
  • Wigan, Lancashire WN6 9EW, United Kingdom
  • Liverpool, Merseyside L1 9AD, United Kingdom
  • Liverpool, Merseyside L22 0LG, United Kingdom
  • Cardiff, South Glamorgan CF14 5GJ, United Kingdom
  • Glasgow, Strathclyde G81 2DR, United Kingdom
  • Birmingham, West Midlands B15 2SQ, United Kingdom
  • Coventry, West Midlands CV1 2TZ, United Kingdom
  • Wolverhampton, West Midlands WV10 9RU, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2011
First posted
Nov 4, 2011
Start
Jan 2004
CompletionActual
Aug 2004
Last update
Dec 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01464983
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 4, 2011
Start date
Jan 2004
Completion
Aug 2004
Last update
Dec 25, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion